Going beyond PARP1/2 inhibition with novel approaches

Can we overcome resistance checkpoint blockade with novel approaches to DDR?

October 7, 2022

Moving On Up

We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat

October 29, 2020

Potential of Immunometabolism to Enhance CAR T cell therapy

How can we use metabolic reprogramming to enhance CAR T cell therapy?

August 18, 2020

A novel way to target KRAS mutant lung cancer

Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer

August 13, 2020

Targeting Glutamine for Cancer Immunometabolism

Can we influence T cell fitness and performance by manipulating metabolic processes?

August 11, 2020

Looking for Signals in Cancer Immunometabolism

In this post we’re taking a look at what we learnt about immunometabolism at AACR20 and some of the early signals from a cancer new product development perspective.

August 6, 2020

A Journey into Immunometabolism and its Potential for Cancer Immunotherapy

The aim of this post is to give you a sense of the potential of immunometabolism to impact T cell fate, fitness, and function.

August 4, 2020

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020

The magic of making proteins disappear

A look at Kymera's protein degrader pipeline

July 21, 2020

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020

Will a novel way to target IL–18 be a winner?

Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?

June 29, 2020

Looking through the window at some novel new product development concepts in oncology

A look at some novel and promising approaches in early oncology new product development

June 24, 2020

How the immune response to cancer can be shaped by the nature of the cancer cells

Looking under the hood in NSCLC at underlying mutations and whether or not they impact survival

June 23, 2020

A rock around the breast cancer clock

Highlights from various breast cancer trials and new pipeline developments

June 2, 2020

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020

Will the next generation SERDs make an impact in ER+ HER2- breast cancer?

An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer

May 21, 2020

ASCO20 Preview on the importance of modality in oncology R&D

Does modality matter in oncology drug development and if so, where?

May 19, 2020

Putting some colour on the TIGIT niche

A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.

May 12, 2020

New directions in adenosine axis targeting

A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview

May 7, 2020

Flying high in the DDR oncology niche

New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.

May 5, 2020

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020

Standing out from the crowd

One particular presentation stood out from the others at AACR20 this year

April 29, 2020

Postcard 2 on Adoptive Cell Therapies from the AACR20 Virtual Meeting

In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session

April 28, 2020

Postcards from Day 1 of AACR20

Commentary on Day 1 of the AACR20 Virtual Meeting

April 28, 2020

One swallow does not a summer make

Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20

April 27, 2020

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020

Reflections on new developments in the KRAS niche

Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2

April 20, 2020

AACR Preview 2 – Pathways to Success in Targeted Therapies

A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies

April 16, 2020

Every cloud has a silver lining

What to watch out for at AACR20 - the first of our meeting previews is here!

April 15, 2020

Impact of Covid–19 on Cancer Conferences

A look at the revised schedule and timelines for upcoming Spring cancer conference season

April 13, 2020

Time is ticking on the bromodomain landscape

Where are they now four years on? A look at the BET/Bromodomain landscape

April 3, 2020

Exploring the immunological links between lung cancer and Covid–19

Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?

March 31, 2020

When oncology and coronavirus worlds collide

Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus

March 4, 2020